Review Compares Efficacy, Safety of Treatments for Hidradenitis Suppurativa
By Elana Gotkine HealthDay Reporter
MONDAY, July 7, 2025 -- The efficacy and safety of currently approved and pipeline medications for moderate-to-severe hidradenitis suppurativa (HS) are compared in a systematic literature review and network meta-analysis published online July 2 in JAMA Dermatology.
Amit Garg, M.D., from Northwell in New Hyde Park, New York, and colleagues compared the efficacy, safety, and tolerability of treatments for moderate-to-severe HS in a systematic literature review of phase 2 and 3 randomized clinical trials. Twenty-five trials, including 5,767 patients and 39 unique treatments, had available Hidradenitis Suppurativa Clinical Response (HiSCR)-50 data.
The researchers found that sonelokimab (120 mg every four weeks and 240 mg every two weeks), lutikizumab (300 mg every two weeks), adalimumab (40 mg once per week), bimekizumab (320 mg every two weeks and 320 mg every four weeks), povorcitinib (15 mg once a day), and secukinumab (300 mg every four weeks and 300 mg every two weeks) were associated with significantly higher HiSCR-50 response rates compared with placebo. The differences between adalimumab (40 mg once per week) and other targeted treatments were mostly not statistically significant. The percentage of patients experiencing serious adverse events ranged from 0 to 10, 0 to 8, and 0 to 6 percent in the placebo groups, the adalimumab (40 mg once per week) groups, and the other active treatment groups, respectively.
"These data do not provide strong support for the superiority of one treatment over adalimumab, or vice versa," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Men With Hidradenitis Suppurativa Perceive Better Physician Communication
WEDNESDAY, July 2, 2025 -- Male patients with hidradenitis suppurativa (HS) perceive better physician communication with respect to demonstrating respect, listening, and...
Socioeconomic Status Tied to New Diagnosis of Hidradenitis Suppurativa
WEDNESDAY, May 14, 2025 -- For dermatology patients, neighborhood-level socioeconomic status (nSES) is associated with a new diagnosis of hidradenitis suppurativa (HS), according...
Rates of Dissatisfaction High for Hidradenitis Suppurativa Care
MONDAY, April 7, 2025 -- The rates of respondent dissatisfaction with current hidradenitis suppurativa (HS) treatment options are high, likely due to undertreatment with available...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.